Anzeige
Meldung des Tages: Lithium explodiert weiter und EMP Metals schaltet jetzt von Story auf Umsetzung

Jazz Pharmaceuticals Aktie News

Aktie
WKN:  A1JS1K ISIN:  IE00B4Q5ZN47 US-Symbol:  JAZZ Branche:  Biotechnologie Land:  Irland
167,49 $
-1,22 $
-0,72%
140,97 € 20:55:35 Uhr
Depot/Watchlist
Marktkapitalisierung *
8,78 Mrd. €
Streubesitz
-
KGV
-
neu: Nachhaltigkeits-Score
37 %
Index-Zuordnung
-
Weiter abwärts? Short handeln - Jetzt mit Hebel 5,76: JU5SHB
Werbung

Jazz Pharmaceuticals News

08.01.26 - PR Newswire
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer PR Newswire
06.01.26 - PR Newswire
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit
Ziihera® (zanidatamab-​hrii) Combinations Achieve Unprecedented Results in First-​Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall ...
17.12.25 - PR Newswire
Jazz Pharmaceuticals to Participate in Upcoming Investor Events
Jazz Pharmaceuticals to Participate in Upcoming Investor Events PR Newswire
17.12.25 - PR Newswire
Jazz Pharmaceuticals to Participate in Upcoming Investor Events
Jazz Pharmaceuticals to Participate in Upcoming Investor Events PR Newswire
05.12.25 - PR Newswire
Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting
Jazz Pharmaceuticals to Present Extensive New Data and Real-​World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-​Resistant Epilepsies at the American ...
02.12.25 - PR Newswire
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-​hrii) Combinations in First-​Line HER2-Positive Locally Advanced or Metastatic ...
18.11.25 - PR Newswire
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference PR Newswire
18.11.25 - PR Newswire
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference PR Newswire
17.11.25 - PR Newswire
Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
Positive HERIZON-​GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-​hrii) as HER2-Targeted Agent-​of-Choice and Ziihera Combination Regimens as New Standard of Care ...
11.11.25 - PR Newswire
Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025
Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025 PR Newswire
05.11.25 - PR Newswire
Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance
Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance PR Newswire
05.11.25 - PR Newswire
Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance
Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance PR Newswire
28.10.25 - PR Newswire
Jazz Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors
Jazz Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors PR Newswire
22.10.25 - PR Newswire
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025 PR Newswire
22.10.25 - PR Newswire
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025 PR Newswire
02.10.25 - PR Newswire
FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-​Line Maintenance Therapy for Extensive-​Stage Small Cell Lung Cancer PR Newswire
22.09.25 - PR Newswire
Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses
Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-​World ...
09.09.25 - PR Newswire
Modeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma
Modeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma PR Newswire
21.08.25 - PR Newswire
Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference
Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference PR Newswire
21.08.25 - PR Newswire
Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference
Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference PR Newswire

Newssuche

Videos

newspaper
22.01.26 +5,88%
Trading Insights vom 22.01.26
Preisschock bei Erdgas! Was sind die Gründe, wie geht man damit um? Gold auf neuem Allzeithoch: wie ... Mehr »